Gilead Sciences, Inc. (GILD) News
Track canonical SquawkNews coverage tagged to GILD, Gilead Sciences, Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 46 indexed stories across 25 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Gilead expands lenacapavir licensing to once-yearly HIV prevention PrEP
Gilead says it expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as PrEP.
EQUITY | Sep 16, 2026, 12:30 PM UTC
L
GILD: Strong HIV growth, new launches, and oncology advances drive portfolio momentum
The event highlighted a robust, diversified portfolio with major advances in HIV prevention and treatment, including strong Yeztugo uptake and new long-acting options. Oncology and immunology pipelines are advancing, wit
NEWS | Sep 15, 2026, 04:42 PM UTC
L
GILD: Diversified launches in HIV, oncology, and immunology drive robust growth and market expansion
The company is at a pivotal growth stage, driven by a diversified portfolio in HIV, oncology, and immunology. New product launches and market expansion strategies are expected to be additive, with significant opportuniti
NEWS | Sep 15, 2026, 04:01 PM UTC
L
Gilead & PAHO Partner To Accelerate Access To Twice-Yearly Lenacapavir Across Latin America & Caribbean
Gilead Sciences, Inc. NASDAQ:GILD
NEWS | Sep 15, 2026, 03:11 PM UTC
L
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP)
NEWS | Sep 15, 2026, 03:10 PM UTC
L
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean
U.S. drugmaker Gilead Sciences NASDAQ:GILD said on Tuesday it had reached an agreement with the Pan American Health Organization to widen access to its HIV prevention drug across Latin America and the Caribbean, as the r
NEWS | Sep 15, 2026, 03:10 PM UTC
L
HSBC maintains a Buy rating on Gilead Sciences; PT raised to $175
Benzinga/TradingView data show HSBC raised its Gilead Sciences price target to $175.00 a share from $155.00 while maintaining a Buy rating. The action is attributed to HSBC.
EQUITY | Sep 10, 2026, 02:04 PM UTC
L
GILD: Diversified pipeline advances in HIV, oncology, and inflammation set up multiple launches and key data
The company is advancing a diversified pipeline across virology, oncology, and inflammation, with multiple new launches and promising clinical data expected in the next year. Key assets include long-acting HIV regimens,
EQUITY | Sep 09, 2026, 05:51 PM UTC
L
GILD pipeline progress across HIV, oncology and inflammation supports growth
Gilead’s diversification has broadened its pipeline across virology, oncology and inflammation, with new launches and promising clinical data in HIV prevention, cell therapy and ADCs. Near-term priorities will shape futu
EQUITY | Sep 09, 2026, 05:38 PM UTC
L
GILD pipeline diversification targets long-acting HIV, cell therapies, ADCs
GILD says pipeline diversification has expanded across virology, oncology and inflammation, with multiple new launches and clinical milestones expected, including long-acting HIV therapies, differentiated cell therapies
EQUITY | Sep 09, 2026, 04:31 PM UTC
L
Assembly Biosciences exercises profit-share option for herpes program
Assembly Biosciences exercised a profit-sharing option under its collaboration with Gilead Sciences for a herpes treatment. It will share 40% of U.S. development costs and profits for the program.
EQUITY | Sep 08, 2026, 08:49 PM UTC
M
GILD, ROIV win FDA nod in weekly biotech buzz
Weekly Buzz highlights FDA nods for GILD and ROIV; also cites a BHVN/LLY deal and SYRE missing a monotherapy goal.
REGULATION | Aug 28, 2026, 02:57 PM UTC
M
FDA approves Gilead’s Bixlenvo for certain adults with HIV
FDA approved Gilead’s Bixlenvo for certain adults with HIV, TradingView News reports.
REGULATION | Aug 27, 2026, 10:41 PM UTC
M
U.S. FDA approves Gilead’s Bixlenvo for HIV adults
U.S. FDA approved Gilead’s Bixlenvo, a once-daily single-tablet option for virologically suppressed adults with HIV, including those on complex regimens.
REGULATION | Aug 27, 2026, 09:50 PM UTC
L
Gilead Sciences to present at Q3 2026 investor conferences
Gilead Sciences plans investor-conference presentations for third quarter 2026.
EQUITY | Aug 26, 2026, 08:05 PM UTC
M
European Commission expands Trodelvy use in metastatic breast cancer
The European Commission expands the role of Gilead’s Trodelvy in first-line metastatic triple-negative breast cancer across PD-L1 status.
REGULATION | Aug 24, 2026, 10:34 AM UTC
M
EU expands Gilead Trodelvy role in metastatic breast cancer
The European Commission grants marketing authorization for Gilead’s Trodelvy with Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer and expands its role across PD-L1 status.
REGULATION | Aug 24, 2026, 10:33 AM UTC
H
Gilead awards U.S. media account to Publicis
Gilead Sciences has awarded Publicis its U.S. Media account after a review that began earlier this year, according to multiple people close to the situation.
MNA | Aug 19, 2026, 07:55 PM UTC
M
Gilead Sciences shares hit 4-week high at $138.33
Gilead Sciences shares rise to $138.33, the highest level since July 2026, with a 5% gain over the past 4 weeks and a 16.83% increase over the last 12 months.
EQUITY | Aug 14, 2026, 06:28 PM UTC
H
KLA, Snowflake, Airbnb, Gilead Chosen On CNBC
KLA, Snowflake, Airbnb and Gilead are picked on CNBC's 'Final Trades'
EARNINGS | Aug 12, 2026, 12:44 PM UTC
M
GILD Returns 11.31% Annually Over 20 Years
Gilead Sciences outperforms the market by 2.04% annually over 20 years
EQUITY | Aug 11, 2026, 10:15 PM UTC
M
GILD Exercises Option for MGNX Bispecific Program
GILD exercises option to license MGNX preclinical bispecific program for $10 million
MNA | Aug 11, 2026, 08:15 PM UTC
H
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
New York Governor Kathy Hochul (D) said President Donald Trump’ s decision to end a Medicare subsidy program will raise prescription drug costs for about 1.3 million New Yorkers, arguing seniors should not have to bear t
GEOPOLITICS | Aug 06, 2026, 07:41 AM UTC
H
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Full
Conference Call
REGULATION | Aug 04, 2026, 09:17 PM UTC
H
Gilead Sees FY Product Sales Of $30.1B-$30.4B
Gilead updates FY sales and earnings guidance
EARNINGS | Aug 04, 2026, 08:09 PM UTC
H
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30
Gilead Sciences (NASDAQ: GILD ) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100 billion-$30.
EARNINGS | Aug 04, 2026, 08:03 PM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 04, 2026, 09:07 AM UTC
H
US Stocks: Earnings After Market
Multiple US companies report earnings
EARNINGS | Aug 03, 2026, 08:49 PM UTC
H
SpaceX Could Swing $204 Billion After Earnings
Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Pro. This is a -selected watc
EARNINGS | Aug 03, 2026, 07:30 PM UTC
H
Eli Lilly Could Swing Over $76 Billion In Value After Earnings
Earnings season will likely keep the tape jumpy this week, and the options market is already sketching out where the biggest post-print air pockets — and upside gaps — could show up, according to Pro. This is a -selected
EARNINGS | Aug 03, 2026, 12:34 PM UTC
H
US FDA Sets August PDUFA Dates
FDA sets PDUFA dates for several biotech companies
REGULATION | Jul 30, 2026, 03:53 PM UTC
L
GILD chmp recommends gilead’s trodelvy® plus keytruda® in pd-(l)1-positive first-line metastatic triple-negative breast cancer
GILD chmp recommends gilead’s trodelvy® plus keytruda® in pd-(l)1-positive first-line metastatic triple-negative breast cancer
EQUITY | Jul 24, 2026, 10:27 AM UTC
H
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings
Prediction market platform Kalshi is expanding into biotech, launching contracts Wednesday night that let traders bet on clinical trial outcomes and drug approvals from companies including Sanofi (NASDAQ: SNY ) and Gilea
REGULATION | Jul 16, 2026, 05:29 PM UTC
H
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
() -- Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-maile
EARNINGS | Jul 08, 2026, 04:58 PM UTC
H
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
() -- Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday. As of July 6, the NYSE Arca Pharmaceutical Index
RATES | Jul 08, 2026, 03:11 PM UTC
H
Gilead price target lowered to $156 from $157 at Truist
Truist lowered the firm's price target on Gilead to $156 from $157 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a trad
EQUITY | Jul 07, 2026, 01:13 PM UTC
H
Gilead price target lowered to $120 from $122 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm's price target on Gilead to $120 from $122 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The bio
RATES | Jul 07, 2026, 11:21 AM UTC
H
What You Missed On Wall Street On Monday
The major averages finished higher to start the week as markets returned from the holiday weekend with a constructive tone and chip stocks rebounded from recent weakness. Last week's weaker-than-expected labor report red
CENTRAL_BANK | Jul 06, 2026, 08:21 PM UTC
L
Okta upgraded, Datadog downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: Scotiabank upgraded Okta (OKTA) to
EQUITY | Jul 06, 2026, 01:48 PM UTC
L
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities
EQUITY | Jul 06, 2026, 11:04 AM UTC
H
GILD Expands Trodelvy Approval
Gilead's Trodelvy receives FDA approval for unresectable locally advanced or metastatic triple-negative breast cancer
EQUITY | Jun 25, 2026, 03:17 PM UTC
H
GILD Receives FDA Approval
Gilead Sciences receives FDA approval for Trodelvy to treat triple-negative breast cancer
EQUITY | Jun 24, 2026, 08:31 PM UTC
H
GILD: FDA Approves Trodelvy
Gilead Sciences receives FDA approval for Trodelvy to treat adult patients with unresectable locally advanced or metastatic triple-negative breast cancer
EQUITY | Jun 24, 2026, 08:30 PM UTC
H
Gilead: FDA OKs Trodelvy
The FDA has approved Gilead's Trodelvy for two indications, one for monotherapy and the other for combination with pembrolizumab.
EQUITY | Jun 24, 2026, 07:00 PM UTC
H
WHO: Ebola Outbreak Outpacing Response
The Ebola outbreak is continuing to outpace the response, according to WHO director Tedros.
EQUITY | Jun 24, 2026, 01:31 PM UTC
H
GILD: EU Approves Trodelvy
GILD's Trodelvy approved by European Commission as first-line treatment for metastatic triple-negative breast cancer patients
EQUITY | Jun 23, 2026, 11:45 AM UTC